# Illumina, Inc. – Consensus ‘buy’ rating and 10.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/illumina-inc.consensus-buy-rating-and-10.4-upside-potential/4121145842
- Published: 2024-03-04T13:33:29+00:00
- Author: Charlotte Edwards

**Illumina, Inc.** with ticker code (ILMN) have now 21 analysts in total covering
the stock. The consensus rating is pointing to ‘buy’. The target price High/Low 
ranges between $258.00 and $85.00 calculating the average target price we see $154.38.
Given that the stocks previous close was at $139.83 and the analysts are correct
then there would likely be a percentage uptick in value of 10.4%. The 50 day MA 
is $139.44 and the 200 day moving average is $151.91. The market cap for the company
is 22.33B. The stock price is currently at: $140.50 USD

 The potential market cap would be $24,648,523,830 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.51 and
a -0.53% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic
and genomic analysis. The Company operates through two segments: Core Illumina and
GRAIL. Its Core Illumina segment offers products and services that serve customers
in the research, clinical and applied markets, and enable the adoption of a variety
of genomic solutions. Its GRAIL segment is a healthcare company focused on early
detection of multiple cancers. Its portfolio of integrated sequencing and microarray
systems, consumables, and analysis tools is designed to accelerate and simplify 
genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing
instruments, allowing customers to manage their biological sample and sequencing
runs, process and analyze the raw genomic data, and derive results. Its BeadArray
technology combines microscopic beads and a substrate in a proprietary manufacturing
process to produce arrays that can perform various assays simultaneously.

Share on:
